Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Tratamiento de la hipertrigliceridemia para la reducción del riesgo cardiovascular","authors":"Carlos Guijarro Herráiz","doi":"10.1016/j.arteri.2025.500816","DOIUrl":"10.1016/j.arteri.2025.500816","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 ","pages":"Article 500816"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eficiencia de las combinaciones a dosis fija de estatina y ezetimiba en el tratamiento de la hipercolesterolemia","authors":"Carlos Guijarro ,&nbsp;Angel Diaz ,&nbsp;Eva Moreno ,&nbsp;Paula Gamonal ,&nbsp;Maria Soler ,&nbsp;Neus Vidal-Vilar ,&nbsp;Maria Rosa Fernandez","doi":"10.1016/j.arteri.2024.500753","DOIUrl":"10.1016/j.arteri.2024.500753","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the clinical and economic benefits derived from increasing the use of fixed-dose combinations of high-intensity statins and ezetimibe in patients at high/very high cardiovascular risk, from the perspective of the Spanish National Health System (SNS).</div></div><div><h3>Methods</h3><div>A baseline scenario (current market shares) was compared with scenarios that increased the use of fixed-dose combinations (alternative: 30% increase; optimized: 69% increase). The potential annual increase in the number of controlled patients, cardiovascular events avoided and the associated savings in direct medical costs were estimated, including the cost of pharmacological treatment, follow-up, and managing cardiovascular events over a three-year time horizon.</div></div><div><h3>Results</h3><div>Over the three years of the study, the baseline scenario estimated a total of 1,552,686 controlled patients and 39,449 cardiovascular events, with a total cost to the SNS of €1,841,057,122. In the alternative scenario, controlled patients would increase by 36.1%, and 139 cardiovascular events would be avoided, resulting in savings for the SNS of €36,116,631. In the optimized scenario, there would be a 64% increase in controlled patients and 250<!--> <!-->cardiovascular events would be avoided, leading to savings of €56,415,300 for the SNS.</div></div><div><h3>Conclusion</h3><div>Increased use of high-intensity statin and ezetimibe fixed-dose combinations in patients with high/very high cardiovascular risk may increase the number of controlled patients, reduce cardiovascular events and produce economic savings from an SNS perspective.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500753"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma expression of a microRNA panel is differentially associated with 1H-NMR lipoprotein profile in rheumatoid arthritis patients","authors":"Dídac Llop ,&nbsp;Silvia Paredes ,&nbsp;Roser Rosales ,&nbsp;Josep Ribalta ,&nbsp;Joan-Carles Vallvé","doi":"10.1016/j.arteri.2025.500759","DOIUrl":"10.1016/j.arteri.2025.500759","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an autoimmune and inflammatory disorder that leads to cartilage and bone deterioration. This inflammatory activity causes extra-articular manifestations, including the acceleration of the atherosclerotic process. However, the exact causes of this accelerated process are under investigation. In this study, we compared the advanced lipid profile between patients with RA, patients with metabolic disorders, and controls. We also explored how microRNAs previously associated with subclinical atherosclerosis in RA are linked to these lipid subfractions in RA.</div></div><div><h3>Methods</h3><div>The study included 219 patients with RA, 82 with metabolic disorders and 64 controls. Clinical evaluations were performed, and blood samples were collected. Quantification of microRNAs (Let7a, 24, 96, 103, 125a, 125b, 132, 146, 191, 223, 425, 451) and measurement of the advanced lipid profile using nuclear magnetic resonance (NMR) were carried out. Kruskal–Wallis tests and multivariate linear models were applied.</div></div><div><h3>Results</h3><div>Patients with RA exhibited elevated total, large, medium, and small VLDL particles compared to controls. Their LDL subfractions were decreased compared to patients with metabolic disorders, with differences with controls. Patients with RA had fewer and smaller HDL particles than both groups. MicroRNA-125a was associated with VLDL subfractions and small LDL particles. Other microRNAs (96, 132, 191, 451) showed associations with certain LDL subfractions.</div></div><div><h3>Conclusions</h3><div>In patients with RA, elevated levels of VLDL particles have been observed, while LDL levels remain similar to controls. The notable association of microRNA-125a with the metabolism of both VLDL and LDL in RA patients suggests its involvement in lipid regulation. This could point to microRNA-125a as a promising therapeutic target to address the increased cardiovascular risks of RA.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500759"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Cómo alcanzar los objetivos en colesterol LDL con los criterios de financiación de los nuevos fármacos hipolipemiantes?","authors":"Antón González-Guerrero ,&nbsp;Elisenda Climent ,&nbsp;David Benaiges ,&nbsp;Juan PedroBotet","doi":"10.1016/j.arteri.2024.500752","DOIUrl":"10.1016/j.arteri.2024.500752","url":null,"abstract":"<div><div>Given the apparent inconsistency of having potent lipid-lowering drugs and the unacceptable rate of achievement of therapeutic goals in LDL cholesterol, it is imperative to define new strategies. In this regard, it is appropriate to detail the key points in planning to start lipid-lowering therapy, emphasizing relevant clinical aspects such as the considerable individual variability in the response to statin therapy, positioning in relation to high-potency statins versus statin<!--> <!-->+<!--> <!-->ezetimibe combination therapy, and the order of choice of lipid-lowering drugs in the therapeutic strategy. An algorithm is then proposed that ensures a personalized approach to lipid-lowering drug treatment in patients with cardiovascular disease and/or familial hypercholesterolemia with the aim of achieving the therapeutic goal in the shortest possible time, taking into account the patient's previous treatment, the funding criteria for new drugs, and the individualized goal of LDL cholesterol reduction.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500752"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La complejidad del riesgo cardiovascular en las mujeres. Revisión descriptiva","authors":"J. Ildefonzo Arocha Rodulfo ,&nbsp;Gestne Aure Fariñez","doi":"10.1016/j.arteri.2024.08.005","DOIUrl":"10.1016/j.arteri.2024.08.005","url":null,"abstract":"<div><h3>Objectives</h3><div>Cardiovascular diseases (CVD) are the greatest threat to the health of women and is the leading cause of death amongst women globally; however, cardiovascular disease in women remains understudied, under-recognized, underdiagnosed, and undertreated. The aim of this descriptive review is to summarize the existing problem and to identify the knowledge gaps in cardiovascular disease research, prevention, treatment, and access to care for women.</div></div><div><h3>Material and methods</h3><div>This is a descriptive review of the literature based on numerous articles published in peer-reviewed journals since the beginning of this century related to the spectrum of cardiovascular disease in women.</div></div><div><h3>Results</h3><div>There are several obstacles to improve cardiovascular disease outcomes in women. One of them is the lack of reliable, effective screening modalities since her participation in clinical trial is quite low. Other concern is the complexity of the female organism with several hormonal changes during her life and the hemodynamics stress during pregnancy. Moreover, in the last stage of their life several cardiometabolic risk factor may appear, most of them not recognized by the health team in primary care attention.</div></div><div><h3>Discussion</h3><div>Effective strategies are required to address inequalities in the diagnosis, treatment and prevention of heart disease in women; to advance innovative solutions for early detection and oriented management; to clarify the underlying biological mechanisms that contribute to sex-specific differences in outcomes; and finally, reduce the global burden of cardiovascular disease in women.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 100736"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asociación entre variables sociodemográficas, hábitos saludables y estrés con diabesidad","authors":"Ángel Arturo López-González ,&nbsp;Emilio Martínez-Almoyna Rifá ,&nbsp;Hernán Paublini Oliveira ,&nbsp;Cristina Martorell Sánchez ,&nbsp;Pedro Juan Tárraga López ,&nbsp;José Ignacio Ramírez-Manent","doi":"10.1016/j.arteri.2024.500754","DOIUrl":"10.1016/j.arteri.2024.500754","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabesity is a pathological condition that combines obesity and type 2 diabetes in the same individual. Due to the current rise in both conditions, the prevalence of diabesity is increasing worldwide. Its etiology is known to be multifactorial; therefore, the aim of this study is to understand how diabesity is associated with various sociodemographic variables, healthy habits, and stress.</div></div><div><h3>Materials and Methods</h3><div>A descriptive, cross-sectional study was conducted on 24,224 Spanish workers to evaluate the association between diabesity and various factors such as age, gender, socioeconomic status, smoking, alcohol consumption, physical activity, adherence to the Mediterranean diet, and stress. The criteria used to define diabesity included body mass index (BMI), body fat (BF), and visceral fat (VF).</div></div><div><h3>Results</h3><div>All the aforementioned variables were found to be associated with diabesity. The highest odds ratios (OR) were observed for age, with values ranging from 5.57 (95% CI: 4.48-6.67) when BF was used as the diabesity criterion to 6.89 (95% CI: 5.60-8.19) when VF was the criterion. Similarly, elevated ORs were observed for male gender, with ORs of 6.77 (95% CI: 5.31-8.24) for VF and 3.34 (95% CI: 2.77-3.94) for BF.</div></div><div><h3>Conclusions</h3><div>In our study, the profile of a person at highest risk of diabesity is a man over 50 years old from a lower socioeconomic status, who is a smoker, regular alcohol consumer, sedentary, with low adherence to the Mediterranean diet, and experiencing high stress levels.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500754"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroARNs asociados a partículas lipídicas con potencial para prevenir o reducir el desarrollo de arteriosclerosis en pacientes con Artritis Reumatoide","authors":"Oriol Alberto Rangel-Zúñiga","doi":"10.1016/j.arteri.2025.500825","DOIUrl":"10.1016/j.arteri.2025.500825","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500825"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"sICAM-1 concentrations are associated with inflammation in contralateral carotid plaque in patients with ischemic stroke","authors":"Núria Puig ,&nbsp;Pol Camps-Renom ,&nbsp;Eduardo Garcia ,&nbsp;Aleyda Benítez-Amaro ,&nbsp;Ana Aguilera-Simón ,&nbsp;Alejandro Fernández-León ,&nbsp;Jose Luis Sanchez Quesada ,&nbsp;Vicenta Llorente-Cortés ,&nbsp;Sonia Benitez","doi":"10.1016/j.arteri.2024.07.002","DOIUrl":"10.1016/j.arteri.2024.07.002","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic plaques in the internal carotid artery are responsible for more than 15% of ischemic strokes. Carotid ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) detects plaque inflammation. Plasma ICAM-1 and LRP1 concentrations have been associated with inflammation in ipsilateral carotid plaque. The aim of the present study was to test the association between the soluble (s) form of these biomarkers and contralateral carotid plaques.</div></div><div><h3>Methods</h3><div>Prospective study conducted in 53 patients with a recent ischemic stroke and at least one atherosclerotic plaque in both carotid arteries. All of the patients underwent an early carotid ¹⁸F-FDG PET, and a blood sample was obtained at 7<!--> <!-->±<!--> <!-->1 days. Several plasma inflammatory markers were evaluated by Multiplex and sLRP1 levels were measured by commercial ELISA. Bivariate and multivariable linear regression was used to assess the association between inflammatory markers and the clinical variables, including contralateral maximum standardized uptake value (SUVmax) and mean SUVmax (mean of contralateral and ipsilateral SUVmax) of ¹⁸F-FDG uptake. Hazard ratio (HR) was estimated with Cox models adjusted for potential confounding factors to evaluate recurrence.</div></div><div><h3>Results</h3><div>Multivariable linear regression analysis showed an independent association between sICAM-1 and sVCAM-1 and mean SUVmax (CI<!--> <!-->=<!--> <!-->−0.064–0.325, <em>p</em> <!-->=<!--> <!-->0.004; CI<!--> <!-->=<!--> <!-->0.079–0.554, <em>p</em> <!-->=<!--> <!-->0.010). In addition, in bivariate regression analysis, sICAM-1 was associated with contralateral SUVmax (CI<!--> <!-->=<!--> <!-->0.049–0.382, <em>p</em> <!-->=<!--> <!-->0.012). Cox regression showed that mean SUVmax was associated with stroke recurrence (HR<!--> <!-->=<!--> <!-->5.604, <em>p</em> <!-->=<!--> <!-->0.044).</div></div><div><h3>Conclusions</h3><div>sICAM-1 was independently associated with mean carotid plaque inflammation and with inflammation in contralateral plaque. sICAM-1 could be an indicator of plaque inflammation even in asymptomatic plaques.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100729"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.arteri.2025.500771","DOIUrl":"10.1016/j.arteri.2025.500771","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 500771"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles in atherosclerosis: Current and forthcoming impact.","authors":"José A. Páramo ,&nbsp;Ana Cenarro ,&nbsp;Fernando Civeira ,&nbsp;Carmen Roncal","doi":"10.1016/j.arteri.2024.03.006","DOIUrl":"10.1016/j.arteri.2024.03.006","url":null,"abstract":"<div><div>Atherosclerosis is the main pathogenic substrate for cardiovascular diseases (CVDs). Initially categorized as a passive cholesterol storage disease, nowadays, it is considered an active process, identifying inflammation among the key players for its initiation and progression. Despite these advances, patients with CVDs are still at high risk of thrombotic events and death, urging to deepen into the molecular mechanisms underlying atherogenesis, and to identify novel diagnosis and prognosis biomarkers for their stratification. In this context, extracellular vesicles (EVs) have been postulated as an alternative in search of novel biomarkers in atherosclerotic diseases, as well as to investigate the crosstalk between the cells participating in the processes leading to arterial remodelling. EVs are nanosized lipidic particles released by most cell types in physiological and pathological conditions, that enclose lipids, proteins, and nucleic acids from parental cells reflecting their activation status. First considered cellular waste disposal systems, at present, EVs have been recognized as active effectors in a myriad of cellular processes, and as potential diagnosis and prognosis biomarkers also in CVDs. This review summarizes the role of EVs as potential biomarkers of CVDs, and their involvement into the processes leading to atherosclerosis.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100718"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}